Daily Eye Drop Could End the Need for Reading Glasses by Late 2025

A groundbreaking development in eye care is set to offer millions of people suffering from age-related near vision loss, known as presbyopia, a chance to ditch their reading glasses. LENZ Therapeutics has received FDA approval for VIZZ, a once-daily prescription eye drop designed to restore clear near vision for up to 10 hours without the need for glasses or contact lenses.

Presbyopia is a natural part of ageing, in which the eye’s lens gradually loses its flexibility, making it difficult to focus on close objects. It commonly affects adults over the age of 40, who often require reading glasses or other corrective aids. Until now, options for managing this condition mostly involved glasses, contact lenses, or surgical procedures.

VIZZ represents a true game-changer in non-surgical treatment. The eye drop contains aceclidine, a chemical that gently contracts the iris sphincter muscle, causing the pupil to shrink in size and create a “pinhole effect.” This effect naturally sharpens focus for near vision without affecting distance vision, unlike some older treatments which may blur distance sight or cause uncomfortable effects.

Clinical trials involving thousands of treatment days showed that VIZZ delivers rapid and durable improvement in near vision, typically within 30 minutes of application and lasting up to 10 hours. Users benefit from extended periods of clear close-up vision with no harsh side effects. Mild side effects reported included brief eye irritation, dim vision, headache, and redness, which generally resolved on their own.

Another advantage of VIZZ is its ease of use. The preservative-free drops come in single-dose vials applied once daily directly to the eyes. Contact lens users need to remove lenses before application and may reinsert them after 10 minutes. Importantly, the drops do not require harsh interventions or ongoing dependence on reading glasses, enhancing the quality of life for presbyopia patients.

VIZZ is expected to launch in the United States by the end of 2025, with sample distributions beginning in October. The company has not yet announced a definite launch date for India. However, Indian ophthalmologists and optometrists are closely monitoring this FDA-approved treatment, recognising its potential to meet the needs of millions affected by presbyopia in India. Given the rising demand for convenient and non-surgical vision solutions, many hope that the innovation will soon become available locally.

This remarkable pharmaceutical solution offers a hopeful and practical alternative for ageing eyes, poised to transform the management of presbyopia worldwide. Those frustrated by the constant need for reading glasses might soon enjoy the freedom of clear near vision simply with a daily drop.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share